Mommox (Mometasone Furoate)

Mommox, a nasal corticosteroid, is employed to manage inflammatory conditions of the nasal passages, providing relief from symptoms associated with allergic and polyposis disorders.

• Allergic rhinitis: reduces nasal congestion, itching, sneezing and rhinorrhea caused by perennial or seasonal allergens.
• Seasonal allergic rhinitis: alleviates symptoms triggered by pollen or other seasonal allergens, improving nasal airflow and quality of life.
• Nasal polyps: decreases polyp size and associated nasal obstruction, helping to prevent recurrence after surgical removal.

• Mometasone furoate binds to intracellular glucocorticoid receptors in nasal mucosal cells, forming a receptor complex that translocates to the nucleus and modulates gene transcription. This action suppresses the production of pro‑inflammatory cytokines, chemokines and adhesion molecules, leading to reduced vascular permeability, edema and inflammatory cell infiltration in the nasal passages. It also down‑regulates inflammatory enzymes such as phospholipase A2, further limiting the synthesis of prostaglandins and leukotrienes.

Mommox may cause local and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects

• Nasal irritation or burning sensation: mild discomfort at the spray site.
• Epistaxis (nosebleeds): occasional bleeding due to mucosal dryness.
• Headache: transient mild headache after use.
• Sore throat or cough: irritation of the throat from spray droplets.
• Dryness of nasal mucosa: feeling of dryness or crusting inside the nose.
• Altered taste or unpleasant taste: temporary change in taste perception.

Serious or Rare Side Effects

• Adrenal suppression with prolonged high‑dose use: reduced endogenous cortisol production.
• Glaucoma or cataract formation: increased intra‑ocular pressure or lens opacity.
• Nasal septal perforation or severe ulceration: tissue breakdown leading to perforation.
• Fungal infection of the nasal passages: opportunistic overgrowth in immunocompromised patients.
• Systemic corticosteroid effects: such as hyperglycemia or mood changes, rarely observed.

When using Mommox, several precautions should be observed to ensure safety and effectiveness.

• Assess for active nasal infection before initiating therapy: avoid use during acute bacterial or fungal sinusitis.
• Limit duration of continuous use: follow physician guidance and reassess after several weeks.
• Use the lowest effective dose: adjust spray frequency according to symptom control.
• Monitor intra‑ocular pressure in patients with glaucoma risk: schedule regular eye examinations.
• Avoid use in patients with known hypersensitivity to mometasone furoate or formulation components: discontinue if reaction occurs.
• Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Mommox can interact with other medications, primarily affecting systemic corticosteroid exposure or local nasal absorption.

Major Interactions (Avoid)

• Concurrent systemic corticosteroids: additive glucocorticoid effects may increase risk of adrenal suppression.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise systemic levels of mometasone furoate.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., erythromycin, ritonavir): possible modest increase in exposure.
• Antihistamines or decongestant nasal sprays: may enhance local irritation or absorption.
• Antifungal agents administered intranasally: potential additive local effects.